Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00225) | |||||
---|---|---|---|---|---|
Name |
Eltrombopag
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
496775-61-2; Promacta; Revolade; (Z)-3'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; SB497115; UNII-S56D65XJ9G; Eltrombopag free base; 3'-[2-[(2Z)-1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; SB-497115; CHEMBL461101; S56D65XJ9G; CHEMBL3186485; CHEBI:85010; Eltrombopag (SB-497115-GR); 496775-61-2 (free base); NCGC00274067-01; (Z)-3'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,; 1807882-48-9; Eltrombopag [INN]; 3-[(5E)-5-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]hydrazinylidene]-6-oxocyclohexa-1,3-dien-1-yl]benzoic acid; SB 497115; Eltrombopag/; Eltrombopag?; AMG531; HSDB 8212; (ZE)-Eltrombopag; PubChem20546; DSSTox_CID_31542; DSSTox_RID_97427; DSSTox_GSID_57753; SCHEMBL18910; MLS006010024; SCHEMBL164270; SCHEMBL211081; SCHEMBL211082; CHEMBL478463; GTPL6961; DTXSID5057753; EX-A443; BCPP000243; HMS3655B14; HMS3743O17; BCP01884; Tox21_113965; ABP000381; ANW-44916; BDBM50248106; MFCD20926253; MFCD21090400; ZINC11679756; ZINC30690955; AKOS015920246; AKOS026750537; ZINC100015243; ZINC100794657; ZINC252551075; ZINC299848778; BCP9000641; CCG-269152; CS-1565; DB06210; EX-7216; SB19101; VA10799; NCGC00274067-02; 376591-99-0; AK-72820; AS-19180; AS-35176; BR-72820; HY-15306; SMR004701208; CAS-496775-61-2; FT-0660417; SW219608-1; SB-497115-GR;SB497115; A12686; A25156; AB01274808-01; AB01274808_02; 775E612; Q411588; Z2216208634; (1,1'-Biphenyl)-3-carboxylic acid, 3'-((2Z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene)hydrazino)-2'-hydroxy-; (E)-3'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; (Z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2'-hydroxybiphenyl-3-carboxylic acid; 3'-[(2Z)- [1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; 3'-{(2z)-2-(1-[3,4-dimethylphenyl]-3-methyl-5-oxo-1,5-dihydro-4h-pyrazol-4-ylidene)diazanyl}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazinyl}-2'-hydroxy[1,1'-biphenyl]-3-carboxylic acid; 3'-{2-[(4E)-1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylidene]hydrazin-1-yl}-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; 3'-{N'-[1-(3,4-dimethyl-phenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3'-{N'-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-pyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid; 3-(3-{2-[(4Z)-1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylidene]hydrazin-1-yl}-2-hydroxyphenyl)benzoic acid; 3-(5-{2-[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl]hydrazin-1-ylidene}-6-oxocyclohexa-1,3-dien-1-yl)benzoic acid; 3-[3-[2-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazole-4-ylidene]hydrazino]-2-hydroxyphenyl]benzoic acid
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Thrombocytopenia | ICD-11: 3B64 | [1] | ||
PubChem CID | |||||
Formula |
C25H22N4O4
|
||||
Canonical SMILES |
CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C
|
||||
InChI |
1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,28,30H,1-3H3,(H,32,33)
|
||||
InChIKey |
SVOQIEJWJCQGDQ-UHFFFAOYSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=135449332"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 442.5 | Topological Polar Surface Area | 115 | |
XlogP | 5.4 | Complexity | 812 | ||
Heavy Atom Count | 33 | Rotatable Bond Count | 5 | ||
Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 7 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Eltrombopag 12.5 mg tablet | Click to Show/Hide the Full List of Formulation(s): 2 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Mannitol; Titanium dioxide; Polyethylene glycol 400; Polysorbate 80; Cellulose, microcrystalline; Hypromelloses; Povidones; Sodium starch glycolate type a potato
|
|||||
Dosage Form | Oral Tablet | |||||
Company | GlaxoSmithKline | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Polysorbate 80 | DIG Info | Prostaglandin G/H synthase 1 (IC50 = 1 uM) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Polyethylene glycol 400 | DIG Info | Albendazole monooxygenase (IC50 = 10.77 mg.mL-1) | [5] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Mannitol; Ferric oxide red; Ferrosoferric oxide; Titanium dioxide; Polyethylene glycol 400; Cellulose, microcrystalline; Hypromelloses; Povidones; Sodium starch glycolate type a potato
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Novartis Pharmaceuticals Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Polyethylene glycol 400 | DIG Info | Albendazole monooxygenase (IC50 = 10.77 mg.mL-1) | [5] | |||
Eltrombopag 25 mg tablet | Click to Show/Hide the Full List of Formulation(s): 2 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Fd&c yellow no. 6; Magnesium stearate; Mannitol; Titanium dioxide; Polyethylene glycol 400; Cellulose, microcrystalline; Hypromelloses; Povidones; Sodium starch glycolate type a potato
|
|||||
Dosage Form | Oral Tablet | |||||
Company | GlaxoSmithKline | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sunset yellow FCF | DIG Info | Solute carrier SLCO2B1 (Ki = 68.4 uM) | [6] | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Polyethylene glycol 400 | DIG Info | Albendazole monooxygenase (IC50 = 10.77 mg.mL-1) | [5] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Mannitol; Ferric oxide red; Ferrosoferric oxide; Titanium dioxide; Polyethylene glycol 400; Cellulose, microcrystalline; Hypromelloses; Povidones; Sodium starch glycolate type a potato
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Novartis Pharmaceuticals Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Polyethylene glycol 400 | DIG Info | Albendazole monooxygenase (IC50 = 10.77 mg.mL-1) | [5] | |||
Eltrombopag 50 mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Fd&c blue no. 2; Magnesium stearate; Mannitol; Titanium dioxide; Polyethylene glycol 400; Cellulose, microcrystalline; Hypromelloses; Povidones; Sodium starch glycolate type a potato
|
|||||
Dosage Form | Oral Tablet | |||||
Company | GlaxoSmithKline; Novartis Pharmaceuticals Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [3] | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Polyethylene glycol 400 | DIG Info | Albendazole monooxygenase (IC50 = 10.77 mg.mL-1) | [5] | |||
Eltrombopag 75 mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Mannitol; Ferric oxide red; Ferrosoferric oxide; Titanium dioxide; Polyethylene glycol 400; Cellulose, microcrystalline; Hypromelloses; Povidones; Sodium starch glycolate type a potato
|
|||||
Dosage Form | Oral Tablet | |||||
Company | GlaxoSmithKline; Novartis Pharmaceuticals Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Polyethylene glycol 400 | DIG Info | Albendazole monooxygenase (IC50 = 10.77 mg.mL-1) | [5] | |||
Eltrombopag 100 mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Mannitol; Ferric oxide yellow; Ferrosoferric oxide; Titanium dioxide; Polyethylene glycol 400; Cellulose, microcrystalline; Hypromelloses; Povidones; Sodium starch glycolate type a potato
|
|||||
Dosage Form | Oral Tablet | |||||
Company | GlaxoSmithKline | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Polyethylene glycol 400 | DIG Info | Albendazole monooxygenase (IC50 = 10.77 mg.mL-1) | [5] | |||
Eltrombopag Olamine eq 50mg acid tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium Stearate; Mannitol; Microcrystalline Cellulose; Povidone; Sodium Starch Glycolate; Hypromellose; Iron Oxide Black; Polyethylene Glycol 400; Titanium Dioxide; Fd&C Blue No. 2 Aluminum Lake
|
|||||
Dosage Form | Tablet | |||||
Company | Novartis | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [3] | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Hypromellose | DIG Info | Cytochrome P450 3A5 (IC50 = 19.4 uM) | [7] | |||
Povidone | DIG Info | Cholesterol 25-hydroxylase (IC50 = 78.3 uM) | [7] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Polyethylene glycol 400 | DIG Info | Albendazole monooxygenase (IC50 = 10.77 mg.mL-1) | [5] | |||
Eltrombopag Olamine eq 12.5mg acid tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium Stearate; Mannitol; Microcrystalline Cellulose; Povidone; Sodium Starch Glycolate; Hypromellose; Iron Oxide Black; Polyethylene Glycol 400; Titanium Dioxide; Polysorbate 80
|
|||||
Dosage Form | Tablet | |||||
Company | Novartis | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Hypromellose | DIG Info | Cytochrome P450 3A5 (IC50 = 19.4 uM) | [7] | |||
Polysorbate 80 | DIG Info | Prostaglandin G/H synthase 1 (IC50 = 1 uM) | [3] | |||
Povidone | DIG Info | Cholesterol 25-hydroxylase (IC50 = 78.3 uM) | [7] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Polyethylene glycol 400 | DIG Info | Albendazole monooxygenase (IC50 = 10.77 mg.mL-1) | [5] | |||
Eltrombopag Olamine eq 100mg acid tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium Stearate; Mannitol; Microcrystalline Cellulose; Povidone; Sodium Starch Glycolate; Polyvinyl Alcohol; Talc; Iron Oxide Black; Polyethylene Glycol 400; Titanium Dioxide; Iron Oxide Yellow; Iron Oxide Black
|
|||||
Dosage Form | Tablet | |||||
Company | Novartis | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Polyvinyl alcohol | DIG Info | Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) | [7] | |||
Povidone | DIG Info | Cholesterol 25-hydroxylase (IC50 = 78.3 uM) | [7] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Polyethylene glycol 400 | DIG Info | Albendazole monooxygenase (IC50 = 10.77 mg.mL-1) | [5] | |||
Eltrombopag Olamine eq 25mg acid tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium Stearate; Mannitol; Microcrystalline Cellulose; Povidone; Sodium Starch Glycolate; Hypromellose; Iron Oxide Black; Polyethylene Glycol 400; Titanium Dioxide; Fd&C Yellow No. 6 Aluminum Lake
|
|||||
Dosage Form | Tablet | |||||
Company | Novartis | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Hypromellose | DIG Info | Cytochrome P450 3A5 (IC50 = 19.4 uM) | [7] | |||
Povidone | DIG Info | Cholesterol 25-hydroxylase (IC50 = 78.3 uM) | [7] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Polyethylene glycol 400 | DIG Info | Albendazole monooxygenase (IC50 = 10.77 mg.mL-1) | [5] | |||
Eltrombopag Olamine eq 75mg acid tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium Stearate; Mannitol; Microcrystalline Cellulose; Povidone; Sodium Starch Glycolate; Hypromellose; Iron Oxide Black; Polyethylene Glycol 400; Titanium Dioxide; Iron Oxide Red
|
|||||
Dosage Form | Tablet | |||||
Company | Novartis | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Hypromellose | DIG Info | Cytochrome P450 3A5 (IC50 = 19.4 uM) | [7] | |||
Povidone | DIG Info | Cholesterol 25-hydroxylase (IC50 = 78.3 uM) | [7] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Polyethylene glycol 400 | DIG Info | Albendazole monooxygenase (IC50 = 10.77 mg.mL-1) | [5] | |||
Eltrombopag Olamine eq 12.5mg acid/packet for suspension | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Mannitol; Sucralose; Xanthan Gum
|
|||||
Dosage Form | For Suspension | |||||
Company | Novartis | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sucralose | DIG Info | Carbonic anhydrase II (Ki = 300 nM) | [8] | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Eltrombopag Olamine eq 25mg acid/packet for suspension | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Mannitol; Sucralose; Xanthan Gum
|
|||||
Dosage Form | For Suspension | |||||
Company | Novartis | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sucralose | DIG Info | Carbonic anhydrase II (Ki = 300 nM) | [8] | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.